Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) is now available.
KYORIN Pharmaceutical Co., Ltd. has entered into an exclusive license agreement with Hinge Bio Inc. to develop and commercialize HB2198, a new drug candidate for systemic lupus erythematosus (SLE) and other diseases, in Japan. This collaboration aligns with KYORIN’s strategic goal to expand its development pipeline and is expected to impact its fiscal year earnings due to the upfront payment to Hinge Bio, which will be recorded as R&D expenses.
The most recent analyst rating on (JP:4569) stock is a Hold with a Yen1653.00 price target. To see the full list of analyst forecasts on KYORIN Pharmaceutical Co.,Ltd. stock, see the JP:4569 Stock Forecast page.
More about KYORIN Pharmaceutical Co.,Ltd.
KYORIN Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of high-value new drugs that address unmet medical needs. The company is committed to expanding its development pipeline as part of its medium-term business plan, ‘Vision 110 —Stage1 —’.
Average Trading Volume: 86,757
Technical Sentiment Signal: Hold
Current Market Cap: Yen78.64B
See more data about 4569 stock on TipRanks’ Stock Analysis page.